Waypoint Bio's platform integrates artificial intelligence, computer vision, and spatial pooled screening to engineer next-generation T cell therapies for solid tumors. The proprietary technology enables in vivo testing of thousands of cell therapy designs simultaneously, measuring hundreds of phenotypes at the single cell level.

The platform compresses years of traditional drug discovery work into a single experiment, allowing researchers to rank and optimize cell therapy designs for safer, more effective treatments. Waypoint's lead program is an in vivo CAR T asset paired with a proprietary next-generation lentiviral vector.

The FDA recently approved the first ever cell therapy for solid tumors, yet innovation in this area has been slow given the challenges of the solid tumor microenvironment. Waypoint Bio addresses this gap by enabling high-throughput in vivo screening of cell therapy designs.

The company initially targets solid tumors, with clinical entry expected in China in late 2026. Waypoint is also extending its platform into biologics and Treg therapies for autoimmune diseases, significantly expanding its addressable market beyond oncology.

Waypoint Bio uniquely combines spatial biology with pooled screening for drug discovery, enabling simultaneous measurement of how cell therapy candidates navigate multiple aspects of the solid tumor microenvironment. This approach addresses the key limitation of traditional screens, which force a choice between scale and quality.

The company's in vivo spatial pooled screening technology tests thousands of therapies in vivo simultaneously, providing multi-dimensional phenotypic data that traditional 1-D readout screens cannot capture. Combined with the Wayfinder LLM that learns from data to suggest new designs, the platform creates a closed loop of design, test, and optimization.